The in vitro activity of the new lipopeptide antibiotic LY146032 was generally four-fold greater (MIC 90 ≤ 0. 5 μg/ml) than that of vancomycin against methicillin-susceptible or methicillin-resistant Staphybcoccus aureus and coagulase-negative species of Staphylococcus. Enterococci, Streptococcus bovis, group B and viridans streptococci, and Corynebacterium group J-K isolates were inhibited by ≤ 4 μg/ml of LY146032, which represented activity equivalent to or greater than that of vancomycin. Unlike vancomycin, LY146032 was bactericidal for Enterococcus faecalis, Enterococcus faecium and Listeria monocytogenes. Due to its bactericidal properties LY146032 appeared to represent an improvement over vancomycin and teicoplanin.
ASJC Scopus subject areas
- Microbiology (medical)